반응식
[N:1]1([C:5]2[NH:9][C:8]3[CH:10]=[CH:11][CH:12]=[CH:13][C:7]=3[N:6]=2)[CH2:4][CH2:3][CH2:2]1.Br[CH2:15][C:16]1[CH:35]=[CH:34][C:19]2/[C:20](=[C:30](/[CH3:33])\[C:31]#[N:32])/[C:21]3[CH:28]=[CH:27][C:26]([F:29])=[CH:25][C:22]=3[O:23][CH2:24][C:18]=2[CH:17]=1>>[N:1]1([C:5]2[N:6]([CH2:15][C:16]3[CH:35]=[CH:34][C:19]4/[C:20](=[C:30](/[CH3:33])\[C:31]#[N:32])/[C:21]5[CH:28]=[CH:27][C:26]([F:29])=[CH:25][C:22]=5[O:23][CH2:24][C:18]=4[CH:17]=3)[C:7]3[CH:13]=[CH:12][CH:11]=[CH:10][C:8]=3[N:9]=2)[CH2:4][CH2:3][CH2:2]1참가 물질
3
실험 절차
[step 2] Using 2-(azetidin-1-yl)-1H-benzo[d]imidazole (40 mg, 0.23 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (84 mg, 0.24 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (61 mg, 59%) was obtained.
후처리
- customobtained in Reference Example 1
출처 및 근거
- ORD 기록
- ord-e9fe6462aa9c4ba2a6e88065de5c1d9a
- 출처 데이터셋
- uspto-grants-2015_03
- 특허 번호
- US08969345B2
연결된 노트
불러오는 중…